Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma : A Danish observational population-based study

Rask Kragh Jørgensen, Rasmus ; Jakobsen, Lasse Hjort ; Eloranta, Sandra ; Smedby, Karin E. ; Pedersen, Robert Schou ; Jørgensen, Judit M. ; Clausen, Michael Roost ; Brown, Peter ; Gang, Anne Ortved and Gade, Inger Lise , et al. (2024) In European Journal of Haematology 113(5). p.641-650
Abstract

Purpose: Etoposide to standard R-CHOP is used for high-risk diffuse large B-cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real-world data study using matching methods was used to test the potential effectiveness of R-CHOEP over R-CHOP. Patients and Methods: This study included patients from the Danish Lymphoma Register diagnosed between 2006 and 2020 at the age of 18–60 years with de novo DLBCL and age-adjusted IPI ≥2. R-CHOEP treated patients were matched 1:1 without replacement to R-CHOP treated patients using a hybrid exact and genetic matching technique. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Results: In total, 396 patients were included; 213 received... (More)

Purpose: Etoposide to standard R-CHOP is used for high-risk diffuse large B-cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real-world data study using matching methods was used to test the potential effectiveness of R-CHOEP over R-CHOP. Patients and Methods: This study included patients from the Danish Lymphoma Register diagnosed between 2006 and 2020 at the age of 18–60 years with de novo DLBCL and age-adjusted IPI ≥2. R-CHOEP treated patients were matched 1:1 without replacement to R-CHOP treated patients using a hybrid exact and genetic matching technique. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Results: In total, 396 patients were included; 213 received R-CHOEP and 183 received R-CHOP. Unadjusted 5-year PFS and OS for R-CHOEP were 69% (95% Confidence intervals [CI]; 63%–76%) and 79% (CI;73%–85%) versus 62% (CI;55%–70%) and 76% (CI;69%–82%) for R-CHOP (log-rank test, PFS p =.25 and OS p =.31). A total of 127 patients treated with R-CHOEP were matched to 127 patients treated with R-CHOP. Matching-adjusted 5-year PFS and OS were 65% (CI; 57%–74%) and 79% (CI; 72%–84%) for R-CHOEP versus 63% (CI; 55%–73%) and 79% (CI;72%–87%) for R-CHOP (log-rank test, PFS p =.90 and OS p =.63). Conclusion: The present study did not confirm superiority of R-CHOEP over R-CHOP for young patients with high-risk DLBCL.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
DLBCL, lymphoma, optimizing treatment outcome, R-CHOP vs R-CHOEP, real world data, toxicity after treatment, treatment of high-risk patients
in
European Journal of Haematology
volume
113
issue
5
pages
10 pages
publisher
Wiley-Blackwell
external identifiers
  • scopus:85199105677
  • pmid:39037054
ISSN
0902-4441
DOI
10.1111/ejh.14275
language
English
LU publication?
yes
id
fe793628-b02d-45b4-bd6e-d83e5d665730
date added to LUP
2024-11-11 15:36:25
date last changed
2025-07-08 11:11:43
@article{fe793628-b02d-45b4-bd6e-d83e5d665730,
  abstract     = {{<p>Purpose: Etoposide to standard R-CHOP is used for high-risk diffuse large B-cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real-world data study using matching methods was used to test the potential effectiveness of R-CHOEP over R-CHOP. Patients and Methods: This study included patients from the Danish Lymphoma Register diagnosed between 2006 and 2020 at the age of 18–60 years with de novo DLBCL and age-adjusted IPI ≥2. R-CHOEP treated patients were matched 1:1 without replacement to R-CHOP treated patients using a hybrid exact and genetic matching technique. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Results: In total, 396 patients were included; 213 received R-CHOEP and 183 received R-CHOP. Unadjusted 5-year PFS and OS for R-CHOEP were 69% (95% Confidence intervals [CI]; 63%–76%) and 79% (CI;73%–85%) versus 62% (CI;55%–70%) and 76% (CI;69%–82%) for R-CHOP (log-rank test, PFS p =.25 and OS p =.31). A total of 127 patients treated with R-CHOEP were matched to 127 patients treated with R-CHOP. Matching-adjusted 5-year PFS and OS were 65% (CI; 57%–74%) and 79% (CI; 72%–84%) for R-CHOEP versus 63% (CI; 55%–73%) and 79% (CI;72%–87%) for R-CHOP (log-rank test, PFS p =.90 and OS p =.63). Conclusion: The present study did not confirm superiority of R-CHOEP over R-CHOP for young patients with high-risk DLBCL.</p>}},
  author       = {{Rask Kragh Jørgensen, Rasmus and Jakobsen, Lasse Hjort and Eloranta, Sandra and Smedby, Karin E. and Pedersen, Robert Schou and Jørgensen, Judit M. and Clausen, Michael Roost and Brown, Peter and Gang, Anne Ortved and Gade, Inger Lise and Larsen, Thomas Stauffer and Jerkeman, Mats and El-Galaly, Tarec Christoffer}},
  issn         = {{0902-4441}},
  keywords     = {{DLBCL; lymphoma; optimizing treatment outcome; R-CHOP vs R-CHOEP; real world data; toxicity after treatment; treatment of high-risk patients}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{641--650}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{European Journal of Haematology}},
  title        = {{Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma : A Danish observational population-based study}},
  url          = {{http://dx.doi.org/10.1111/ejh.14275}},
  doi          = {{10.1111/ejh.14275}},
  volume       = {{113}},
  year         = {{2024}},
}